Hellmann MD, et al. Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy. IASLC 2018, abstract OA05.01.
MUC16-mutatie geassocieerd met betere overleving bij maagkanker
aug 2018 | Immuuntherapie, Maag-darm-leveroncologie